Compounds > rpr 100893
Page last updated: 2024-09-04

rpr 100893 and Migraine Disorders

rpr 100893 has been researched along with Migraine Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Diener, HC1
Suzuki, N1

Reviews

1 review(s) available for rpr 100893 and Migraine Disorders

ArticleYear
[Migraine and neurotransmitters].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Feb-10, Volume: 87, Issue:2

    Topics: GABA Agents; Indoles; Isoindoles; Migraine Disorders; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Serotonin Antagonists; Sumatriptan; Valproic Acid

1998

Trials

1 trial(s) available for rpr 100893 and Migraine Disorders

ArticleYear
RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.
    Cephalalgia : an international journal of headache, 2003, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Migraine Disorders; Substance P

2003

Other Studies

1 other study(ies) available for rpr 100893 and Migraine Disorders

ArticleYear
Dapitant. RPR 100893.
    Drugs in R&D, 1999, Volume: 2, Issue:6

    Topics: Animals; Clinical Trials, Phase II as Topic; Double-Blind Method; Electric Stimulation; Humans; Indoles; Isoindoles; Migraine Disorders; Neurokinin-1 Receptor Antagonists; Placebos; Randomized Controlled Trials as Topic; Trigeminal Ganglion

1999